Early Stimulation of TREK Channel Transcription and Activity Induced by Oxaliplatin-Dependent Cytosolic Acidification.
Action Potentials
/ drug effects
Amiloride
/ pharmacology
Animals
Antineoplastic Agents
/ adverse effects
Capsaicin
/ pharmacology
Epithelial Sodium Channel Blockers
/ pharmacology
Ganglia, Spinal
/ drug effects
Humans
Hydrogen-Ion Concentration
/ drug effects
Male
Mice
Mice, Inbred BALB C
Models, Biological
Neurons
/ drug effects
Oxaliplatin
/ adverse effects
Patch-Clamp Techniques
Peripheral Nervous System Diseases
/ chemically induced
Potassium Channels, Tandem Pore Domain
/ agonists
Primary Cell Culture
Sodium-Hydrogen Exchanger 1
/ antagonists & inhibitors
Transcriptional Activation
DRG neurons
Na+/H+ exchanger
TREK channels
TRPV1
electrophysiology
neuropathic pain
oxaliplatin
pH
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Sep 2020
28 Sep 2020
Historique:
received:
11
09
2020
accepted:
27
09
2020
entrez:
1
10
2020
pubmed:
2
10
2020
medline:
26
2
2021
Statut:
epublish
Résumé
Oxaliplatin-induced peripheral neuropathy is characterized by an acute hyperexcitability syndrome triggered/exacerbated by cold. The mechanisms underlying oxaliplatin-induced peripheral neuropathy are unclear, but the alteration of ion channel expression and activity plays a well-recognized central role. Recently, we found that oxaliplatin leads to cytosolic acidification in dorsal root ganglion (DRG) neurons. Here, we investigated the early impact of oxaliplatin on the proton-sensitive TREK potassium channels. Following a 6-h oxaliplatin treatment, both channels underwent a transcription upregulation that returned to control levels after 42 h. The overexpression of TREK channels was also observed after in vivo treatment in DRG cells from mice exposed to acute treatment with oxaliplatin. Moreover, both intracellular pH and TREK channel transcription were similarly regulated after incubation with amiloride, an inhibitor of the Na
Identifiants
pubmed: 32998392
pii: ijms21197164
doi: 10.3390/ijms21197164
pmc: PMC7584002
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Epithelial Sodium Channel Blockers
0
Potassium Channels, Tandem Pore Domain
0
Sodium-Hydrogen Exchanger 1
0
potassium channel protein TREK-1
0
Oxaliplatin
04ZR38536J
Amiloride
7DZO8EB0Z3
Capsaicin
S07O44R1ZM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AEI-MCII
ID : RTI2018-097189-B-C21
Organisme : UMH
ID : PAR-2019
Organisme : AIRC
ID : IG 2016 Id.18631
Organisme : MIUR
ID : PRIN 2017ZFJCS3
Références
J Physiol. 2005 Apr 1;564(Pt 1):103-16
pubmed: 15677687
Pain. 2014 Dec;155(12):2534-44
pubmed: 25239074
Pain. 2020 Feb;161(2):405-415
pubmed: 31634341
Sci Rep. 2018 Oct 10;8(1):15084
pubmed: 30305703
EMBO J. 1998 Aug 3;17(15):4283-90
pubmed: 9687497
J Biol Chem. 1993 Aug 5;268(22):16369-77
pubmed: 8393860
J Neurosci. 2011 Jan 26;31(4):1375-85
pubmed: 21273422
BMC Genomics. 2004 Jul 16;5(1):46
pubmed: 15257760
Nat Rev Mol Cell Biol. 2010 Jan;11(1):50-61
pubmed: 19997129
Brain Res. 2017 Jun 15;1665:95-104
pubmed: 28438532
EMBO Mol Med. 2011 May;3(5):266-78
pubmed: 21438154
Toxics. 2015 Aug 07;3(3):304-321
pubmed: 29051466
J Neurosci. 2014 Jan 22;34(4):1494-509
pubmed: 24453337
Neuroscience. 2011 Jul 14;186:179-87
pubmed: 21549810
PLoS One. 2018 Jun 21;13(6):e0199282
pubmed: 29928032
EMBO J. 2009 May 6;28(9):1308-18
pubmed: 19279663
Br J Pharmacol. 2019 Jan;176(2):256-266
pubmed: 30325008
Eur J Neurosci. 1999 Aug;11(8):2783-92
pubmed: 10457175
Int J Mol Sci. 2019 May 14;20(10):
pubmed: 31091651
J Biol Chem. 2011 Jan 21;286(3):1719-29
pubmed: 21068392
Front Mol Neurosci. 2012 Mar 05;5:21
pubmed: 22403526
Mol Pain. 2017 Jan-Dec;13:1744806917714693
pubmed: 28580836
Cancer Res. 2010 Oct 1;70(19):7514-22
pubmed: 20841472
Mol Microbiol. 1993 Apr;8(1):5-14
pubmed: 8388532
Front Physiol. 2014 Feb 13;5:43
pubmed: 24592239
Nat Neurosci. 2014 Feb;17(2):153-63
pubmed: 24473263
J Physiol. 2007 Aug 15;583(Pt 1):57-69
pubmed: 17540699
J Biol Chem. 2000 Sep 15;275(37):28398-405
pubmed: 10880510
Cancer Res. 2007 Aug 15;67(16):7865-74
pubmed: 17699793
Mol Pain. 2011 Apr 26;7:29
pubmed: 21521528
Pain Res Treat. 2013;2013:217864
pubmed: 23431433
Physiol Genomics. 2004 Aug 11;18(3):331-9
pubmed: 15306696
Biomol Ther (Seoul). 2016 May 1;24(3):252-9
pubmed: 27133259
Int J Mol Sci. 2019 Mar 22;20(6):
pubmed: 30909387
Annu Rev Neurosci. 2020 Jul 8;43:207-229
pubmed: 32084327
Mol Pain. 2012 Jul 28;8:55
pubmed: 22839205
Curr Med Chem. 2015;22(32):3682-94
pubmed: 26423088
Br J Pharmacol. 2015 Apr;172(7):1728-38
pubmed: 25409575
Mol Microbiol. 2002 Dec;46(5):1319-33
pubmed: 12453218
J Neurophysiol. 2016 Jun 1;115(6):3217-28
pubmed: 27052585
EMBO J. 2006 Jun 7;25(11):2368-76
pubmed: 16675954
Channels (Austin). 2011 Sep-Oct;5(5):402-9
pubmed: 21829087
Neuro Oncol. 2012 Sep;14 Suppl 4:iv45-54
pubmed: 23095830
PLoS One. 2017 Oct 11;12(10):e0186250
pubmed: 29020118
Biochem Biophys Res Commun. 2005 Feb 25;327(4):1163-9
pubmed: 15652517
Mol Biol Cell. 2001 Feb;12(2):323-37
pubmed: 11179418